ADTX is expected to report earnings to rise 4,058.27% to -11559 cents per share on August 30
Q2'23
Est.
$-115.60
Q1'23
Est.
$-2.78
Q4'22
Missed
by $0.48
Q3'22
Missed
by $1.38
Q2'22
Missed
by $253.50
The last earnings report on May 31 showed earnings per share of -277 cents, meeting the estimate of -277 cents. With 988.84K shares outstanding, the current market capitalization sits at 3.04M.
a life sciences company which engages in the development of nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients as well as address autoimmune diseases and allergies